NASDAQ:KTTA Pasithea Therapeutics 3/30/2026 Earnings Report $0.70 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$0.73 +0.03 (+3.74%) As of 05/22/2026 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pasithea Therapeutics EPS ResultsActual EPS-$0.89Consensus EPS -$0.18Beat/MissMissed by -$0.71One Year Ago EPSN/APasithea Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.10 millionBeat/MissN/AYoY Revenue GrowthN/APasithea Therapeutics Announcement DetailsQuarterDate3/30/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsPasithea Therapeutics' next earnings date is estimated for Wednesday, June 3, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Pasithea Therapeutics Earnings HeadlinesQ2 EPS Estimate for Pasithea Therapeutics Lifted by AnalystMay 25 at 1:11 AM | americanbankingnews.comPasithea Therapeutics (NASDAQ:KTTA) Stock Price Down 1.3% - Here's WhyMay 19, 2026 | americanbankingnews.comThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When the SpaceX and xAI S-1 filing hits the SEC in June, analysts will comb through supplier disclosures and this company's name is expected to surface. Dylan Jovine has identified the ticker and laid out the full investment thesis. The stock is still quiet - but that window may be closing fast.May 26 at 1:00 AM | Behind the Markets (Ad)Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical OfficerMay 4, 2026 | globenewswire.comIs Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?May 3, 2026 | finance.yahoo.comPasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)April 20, 2026 | markets.businessinsider.comSee More Pasithea Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pasithea Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pasithea Therapeutics and other key companies, straight to your email. Email Address About Pasithea TherapeuticsPasithea Therapeutics (NASDAQ:KTTA), Inc. (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways. The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders. Pasithea’s research approach centers on human-derived antibodies with tailored specificity and functionality, addressing areas of high unmet need such as severe chronic inflammatory conditions. By applying its platform to a range of targets, Pasithea seeks to advance innovative therapies toward regulatory milestones and strategic partnerships. Headquartered in Seattle, Washington, Pasithea Therapeutics maintains research and development operations in the Pacific Northwest, with teams dedicated to antibody engineering, translational science and regulatory strategy. The company is led by a management team with experience in biotechnology innovation, clinical development and commercialization, supported by a board of directors and scientific advisors drawn from leading academic and industry institutions. Pasithea continues to explore collaborations with academic centers and pharmaceutical partners to accelerate its therapeutic programs.View Pasithea Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Ross Stores Earnings Beat Sends Stock To New HighsWas Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?Workday Validates AI Flywheel: Stock Price Recovery BeginsApparel Earnings Winners and Losers: Ralph Lauren Takes OffWhy Walmart, Target and TJX Got Such Different Reactions After EarningsThe Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May AppearOverextended, e.l.f. Beauty Is Primed to Rebound in Back Half Upcoming Earnings Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
